Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma, Company Expects to Report Initial Clinical Data in 2021

Sirnaomics, Inc. announced dose administration for the first patient in a Phase IIa clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.